Claire Vignand-Courtin

Assistance Publique – Hôpitaux de Paris, Lutetia Parisorum, Île-de-France, France

Are you Claire Vignand-Courtin?

Claim your profile

Publications (3)3.16 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Sunitinib is an antineoplastic agent, specifically a tyrosine kinase inhibitor. Thanks to its targeted action, this drug is relatively well tolerated. The main side effects are asthenia, gastrointestinal disturbances, and dermatological effects. The aim of our study was to collect information about dermatological side effects and assess them in patients treated with sunitinib. A retrospective study was performed on 8 patients treated with sunitinib between January 2006 and July 2009. Twelve different types of side effects were observed: genital lesion (9), cutaneous eruption (7), hand-foot syndrome (6), yellow discoloration of skin (4), hair depigmentation (4), xerosis (4), pigmented lesion (4), vascular lesion (3), erythema (3), splinter haemorrhage of fingernails (1), facial oedema (1), and pruritus (1). To date vascular and pigmented lesions associated with sunitinib have not been recorded in literature, genital lesions have only been described in the scrotal region. These genital lesions led to discontinuation of treatment by 4 patients in our study. Although the risk/benefit ratio is favourable for sunitinib, all health care professionals must be aware of the risk of such adverse events. When genital lesions are observed, dose adjustment is recommended. Thorough clinical examination and patient interviews are necessary to detect these effects.
    International journal of clinical pharmacy. 03/2012; 34(2):286-9.
  • V Brunie, M-C Lott, J Guiader, M Slama, A Rieutord, C Vignand-Courtin
    [Show abstract] [Hide abstract]
    ABSTRACT: Heart failure is a chronic, common and severe disease. It leads to frequent hospitalizations and decrease of patient's quality of life. A therapeutic patient education program, named "school of heart failure" was implemented at Antoine-Béclère hospital. To assess the effectiveness of this program. This therapeutic patient education program included patients with heart failure, hospitalized in a cardiology unit. Four types of evaluation were carried out: evaluation of patients' skills before they leave the hospital, patient's knowledge (associated with the degree of certainty), satisfaction regarding the program and self-assessment of changes in their lifestyle 3 months after discharge. Twenty-four patients were included in 9 months. The program's evaluation showed promising results with respect to the acquisition of skills (94%), the improvement of patients' knowledge associated with self-confidence increase, their satisfaction towards the program (80%) and their ability to change their habits (75%). Self-assessment has demonstrated changes in their lifestyle. These preliminary results are promising according to the program's effectiveness and its ability to meet patients' educational needs. The program was certified by French authorities in 2011. Knowledge and skills acquisition will have to be confirmed on long term.
    Annales de cardiologie et d'angeiologie 10/2011; 61(2):74-80. · 0.21 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: prostacyclin is the main arachidonic acid metabolite and its decrease has been proven to be important in the pathophysiology of the pulmonary arterial hypertension (PAH). Epoprostenol has been the first analog of prostacyclin to be approved for the treatment of PAH and despite the development of therapeutic options, the last recommendations of European Societies of Cardiology and Pulmonology maintain it as the first choice therapy for severe patients in the WHO functional class IV. In this review, we focus on pharmacokinetics of epoprostenol characterized by its instability in aqueous biological fluids and compare its pharmacokinetics with other stable analogs of prostacyclin. Moreover, pharmacodynamics, clinical efficacy and safety of epoprostenol were studied. a literature search and review of the studies published on epoprostenol were carried out using the MEDLINE database. the paper provides the reader with information on epoprostenol pharmacokinetics and comparison with other analogs of prostacyclin. This paper also provides data on pharmacodynamics, clinical efficacy, safety and tolerability of epoprostenol. despite epoprostenol's short half-life and complicated delivery system, this treatment remains the first choice therapy for severe PAH patients.
    Expert Opinion on Drug Metabolism &amp Toxicology 12/2010; 6(12):1587-98. · 2.94 Impact Factor